Clinical application of Bioartificial liver support systems

To review the present status of bioartificial liver (BAL) devices and their obtained clinical results. Acute liver failure (ALF) is a disease with a high mortality. Standard therapy at present is liver transplantation. Liver transplantation is hampered by the increasing shortage of organ donors, res...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgery 2004-08, Vol.240 (2), p.216-230
Main Authors: VAN DE KERKHOVE, Maarten Paul, HOEKSTRA, Ruurdtje, CHAMULEAU, Robert A. F. M, VAN GULIK, Thomas M
Format: Article
Language:English
Subjects:
Biological and medical sciences
Critical Illness
Extracorporeal Circulation - methods
Female
Follow-Up Studies
General aspects
Humans
Liver Failure - diagnosis
Liver Failure - mortality
Liver Failure - therapy
Liver Transplantation - methods
Liver, Artificial
Male
Medical sciences
Review
Risk Assessment
Survival Analysis
Treatment Outcome
Waiting Lists
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To review the present status of bioartificial liver (BAL) devices and their obtained clinical results. Acute liver failure (ALF) is a disease with a high mortality. Standard therapy at present is liver transplantation. Liver transplantation is hampered by the increasing shortage of organ donors, resulting in high incidence of patients with ALF dying on the transplantation waiting list. Among a variety of liver assist therapies, BAL therapy is marked as the most promising solution to bridge ALF patients to liver transplantation or to liver regeneration, because several BAL systems showed significant survival improvement in animal ALF studies. Until today, clinical application of 11 different BAL systems has been reported. A literature review was performed using MEDLINE and additional library searches. Only BAL systems that have been used in a clinical trial were included in this review. Eleven BAL systems found clinical application. Three systems were studied in a controlled trial, showing no significant survival benefits, in part due to the insufficient number of patients included. The other systems were studied in a phase I trial or during treatment of a single patient and all showed to be safe. Most BAL therapies resulted in improvement of clinical and biochemical parameters. Bioartificial liver therapy for bridging patients with ALF to liver transplantation or liver regeneration is promising. Its clinical value awaits further improvement of BAL devices, replacement of hepatocytes of animal origin by human hepatocytes, and assessment in controlled clinical trials.
ISSN:0003-4932
1528-1140
DOI:10.1097/01.sla.0000132986.75257.19